The independent predictors of non‐alcoholic steatohepatitis and its individual histological features Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment
The diagnosis of non-alcoholic steatohepatitis (NASH) is based on the individual histological features: steatosis, lobular inflammation and ballooning. Non-alcoholic fatty liver disease (NAFLD) activity score (NAS ≥ 5) is used in clinical trials. Fibrosis dictates long-term NAFLD prognosis. Recently...
Saved in:
Published in | Hepatology research Vol. 46; no. 11; pp. 1074 - 1087 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
01.10.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The diagnosis of non-alcoholic steatohepatitis (NASH) is based on the individual histological features: steatosis, lobular inflammation and ballooning. Non-alcoholic fatty liver disease (NAFLD) activity score (NAS ≥ 5) is used in clinical trials. Fibrosis dictates long-term NAFLD prognosis. Recently, more-than-mild portal inflammation has raised interest as a marker of NAFLD severity. We assessed the independent predictors of: (I) individual histological lesions of NASH; (II) diagnosis of NASH; (III) significant (stage ≥2) and advanced (stage ≥3) fibrosis; and (IV) more-than-mild portal inflammation.
Data from 118 consecutive biopsy-proven NAFLD patients observed at our institution were retrospectively analyzed.
At stepwise multivariate logistic regression analyses, independent predictors were as follows. For the individual histological features of NASH: insulin resistance (IR), assessed with Homeostasis Model Assessment-IR (HOMA-IR), serum uric acid (SUA) and serum total cholesterol (TCH) for moderate-to-severe steatosis; waist circumference (waist), HOMA-IR and TCH for lobular inflammation; waist, HOMA-IR, metabolic syndrome (MS), serum alanine aminotransferase (ALT), SUA and TCH for ballooning. For NASH diagnosis: waist, HOMA-IR, MS, ALT, SUA and TCH (Brunt et al.'s classification); ALT, SUA and TCH for NAS ≥ 5. For significant and advanced fibrosis, respectively: waist, MS and ALT; age, platelets, HOMA-IR, diabetes and TCH. For more-than-mild portal inflammation: serum aspartate aminotransferase (AST), serum iron, NAS ≥ 5 and significant liver fibrosis.
HOMA-IR, SUA, MS, ALT and TCH are independent predictors of NASH and its individual histological lesions, notably including fibrosis. Based on our findings, these factors should be considered major pathogenic drivers of NASH and, by inference, potential targets for treatment. |
---|---|
AbstractList | The diagnosis of non-alcoholic steatohepatitis (NASH) is based on the individual histological features: steatosis, lobular inflammation and ballooning. Non-alcoholic fatty liver disease (NAFLD) activity score (NAS ≥ 5) is used in clinical trials. Fibrosis dictates long-term NAFLD prognosis. Recently, more-than-mild portal inflammation has raised interest as a marker of NAFLD severity. We assessed the independent predictors of: (I) individual histological lesions of NASH; (II) diagnosis of NASH; (III) significant (stage ≥2) and advanced (stage ≥3) fibrosis; and (IV) more-than-mild portal inflammation.
Data from 118 consecutive biopsy-proven NAFLD patients observed at our institution were retrospectively analyzed.
At stepwise multivariate logistic regression analyses, independent predictors were as follows. For the individual histological features of NASH: insulin resistance (IR), assessed with Homeostasis Model Assessment-IR (HOMA-IR), serum uric acid (SUA) and serum total cholesterol (TCH) for moderate-to-severe steatosis; waist circumference (waist), HOMA-IR and TCH for lobular inflammation; waist, HOMA-IR, metabolic syndrome (MS), serum alanine aminotransferase (ALT), SUA and TCH for ballooning. For NASH diagnosis: waist, HOMA-IR, MS, ALT, SUA and TCH (Brunt et al.'s classification); ALT, SUA and TCH for NAS ≥ 5. For significant and advanced fibrosis, respectively: waist, MS and ALT; age, platelets, HOMA-IR, diabetes and TCH. For more-than-mild portal inflammation: serum aspartate aminotransferase (AST), serum iron, NAS ≥ 5 and significant liver fibrosis.
HOMA-IR, SUA, MS, ALT and TCH are independent predictors of NASH and its individual histological lesions, notably including fibrosis. Based on our findings, these factors should be considered major pathogenic drivers of NASH and, by inference, potential targets for treatment. The diagnosis of non-alcoholic steatohepatitis (NASH) is based on the individual histological features: steatosis, lobular inflammation and ballooning. Non-alcoholic fatty liver disease (NAFLD) activity score (NAS ≥ 5) is used in clinical trials. Fibrosis dictates long-term NAFLD prognosis. Recently, more-than-mild portal inflammation has raised interest as a marker of NAFLD severity. We assessed the independent predictors of: (I) individual histological lesions of NASH; (II) diagnosis of NASH; (III) significant (stage ≥2) and advanced (stage ≥3) fibrosis; and (IV) more-than-mild portal inflammation.AIMThe diagnosis of non-alcoholic steatohepatitis (NASH) is based on the individual histological features: steatosis, lobular inflammation and ballooning. Non-alcoholic fatty liver disease (NAFLD) activity score (NAS ≥ 5) is used in clinical trials. Fibrosis dictates long-term NAFLD prognosis. Recently, more-than-mild portal inflammation has raised interest as a marker of NAFLD severity. We assessed the independent predictors of: (I) individual histological lesions of NASH; (II) diagnosis of NASH; (III) significant (stage ≥2) and advanced (stage ≥3) fibrosis; and (IV) more-than-mild portal inflammation.Data from 118 consecutive biopsy-proven NAFLD patients observed at our institution were retrospectively analyzed.METHODSData from 118 consecutive biopsy-proven NAFLD patients observed at our institution were retrospectively analyzed.At stepwise multivariate logistic regression analyses, independent predictors were as follows. For the individual histological features of NASH: insulin resistance (IR), assessed with Homeostasis Model Assessment-IR (HOMA-IR), serum uric acid (SUA) and serum total cholesterol (TCH) for moderate-to-severe steatosis; waist circumference (waist), HOMA-IR and TCH for lobular inflammation; waist, HOMA-IR, metabolic syndrome (MS), serum alanine aminotransferase (ALT), SUA and TCH for ballooning. For NASH diagnosis: waist, HOMA-IR, MS, ALT, SUA and TCH (Brunt et al.'s classification); ALT, SUA and TCH for NAS ≥ 5. For significant and advanced fibrosis, respectively: waist, MS and ALT; age, platelets, HOMA-IR, diabetes and TCH. For more-than-mild portal inflammation: serum aspartate aminotransferase (AST), serum iron, NAS ≥ 5 and significant liver fibrosis.RESULTSAt stepwise multivariate logistic regression analyses, independent predictors were as follows. For the individual histological features of NASH: insulin resistance (IR), assessed with Homeostasis Model Assessment-IR (HOMA-IR), serum uric acid (SUA) and serum total cholesterol (TCH) for moderate-to-severe steatosis; waist circumference (waist), HOMA-IR and TCH for lobular inflammation; waist, HOMA-IR, metabolic syndrome (MS), serum alanine aminotransferase (ALT), SUA and TCH for ballooning. For NASH diagnosis: waist, HOMA-IR, MS, ALT, SUA and TCH (Brunt et al.'s classification); ALT, SUA and TCH for NAS ≥ 5. For significant and advanced fibrosis, respectively: waist, MS and ALT; age, platelets, HOMA-IR, diabetes and TCH. For more-than-mild portal inflammation: serum aspartate aminotransferase (AST), serum iron, NAS ≥ 5 and significant liver fibrosis.HOMA-IR, SUA, MS, ALT and TCH are independent predictors of NASH and its individual histological lesions, notably including fibrosis. Based on our findings, these factors should be considered major pathogenic drivers of NASH and, by inference, potential targets for treatment.CONCLUSIONHOMA-IR, SUA, MS, ALT and TCH are independent predictors of NASH and its individual histological lesions, notably including fibrosis. Based on our findings, these factors should be considered major pathogenic drivers of NASH and, by inference, potential targets for treatment. |
Author | Romagnoli, Dante Lonardo, Amedeo Ballestri, Stefano Nascimbeni, Fabio |
Author_xml | – sequence: 1 givenname: Stefano surname: Ballestri fullname: Ballestri, Stefano organization: Internal Medicine, Pavullo Hospital Azienda USL, Modena Italy – sequence: 2 givenname: Fabio surname: Nascimbeni fullname: Nascimbeni, Fabio organization: Internal Medicine, NOCSAE Baggiovara Azienda USL, Modena Italy – sequence: 3 givenname: Dante surname: Romagnoli fullname: Romagnoli, Dante organization: Internal Medicine, NOCSAE Baggiovara Azienda USL, Modena Italy, Outpatient Liver Clinic and Internal Medicine, NOCSAE, Baggiovara Azienda USL, Modena Italy – sequence: 4 givenname: Amedeo surname: Lonardo fullname: Lonardo, Amedeo organization: Internal Medicine, NOCSAE Baggiovara Azienda USL, Modena Italy, Outpatient Liver Clinic and Internal Medicine, NOCSAE, Baggiovara Azienda USL, Modena Italy |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26785389$$D View this record in MEDLINE/PubMed |
BookMark | eNptkM1KxDAQgIOsuO7qxQeQHkXo2jRtmj3K4h8seFnBW0mTiY1km5qkgjcfwWf0Scy6qwdxDvMD38zAN0GjznaA0AnOZjjGRQu9m-GclnQPHWJW5WlGisdR7AmjKSUFHaOJ989ZhqssLw7QOKcVKwmbHyK1aiHRnYQeYupC0juQWgTrfGJVEj99vn9wI2xrjRaJD8CDjQ950EH7hHcy0cFvLuhXLQduklb7YI190iIOKuKDA3-E9hU3Ho53dYoerq9Wi9t0eX9zt7hcpoKUVUjnlIpCEFbiqmz4nHIA4LJRAuOKc0wII1jmTLJKqFyRhoCSjcxjpbQitCFTdLa92zv7MoAP9Vp7AcbwDuzga8xySgtWMhzR0x06NGuQde_0mru3-sdNBM63gHDWewfqF8FZvRFfb8TX3-IjnP2BhQ5Rku2C49r8t_IFUD2KSw |
CitedBy_id | crossref_primary_10_1097_MD_0000000000007853 crossref_primary_10_1097_MD_0000000000034957 crossref_primary_10_4254_wjh_v10_i8_530 crossref_primary_10_1080_17474124_2025_2477249 crossref_primary_10_26442_terarkh201890863_68 crossref_primary_10_3390_ijerph19116424 crossref_primary_10_1139_facets_2023_0146 crossref_primary_10_1097_TIN_0000000000000126 crossref_primary_10_3390_ijms22136969 crossref_primary_10_1007_s00592_018_1266_0 crossref_primary_10_1186_s12986_016_0149_z crossref_primary_10_3390_metabo14080408 crossref_primary_10_14309_ajg_0000000000001375 crossref_primary_10_1007_s11695_017_2829_9 crossref_primary_10_3390_livers4010010 crossref_primary_10_3389_fendo_2024_1455132 crossref_primary_10_1186_s12876_021_01978_0 crossref_primary_10_2147_DMSO_S358744 crossref_primary_10_19163_1994_9480_2022_19_2_33_42 crossref_primary_10_2478_abm_2022_0003 crossref_primary_10_1016_j_taap_2023_116770 crossref_primary_10_1016_j_dld_2018_01_126 crossref_primary_10_1016_j_dld_2017_01_147 crossref_primary_10_1111_jgh_13648 crossref_primary_10_37349_emed_2020_00018 crossref_primary_10_1210_clinem_dgac190 crossref_primary_10_1007_s42000_018_0021_9 crossref_primary_10_1002_hep4_1077 crossref_primary_10_1515_hmbci_2018_0047 crossref_primary_10_1097_MEG_0000000000000931 crossref_primary_10_1016_j_jhep_2017_09_021 crossref_primary_10_1016_j_metabol_2017_04_003 crossref_primary_10_1002_14651858_CD015033_pub2 crossref_primary_10_3390_ijerph16193570 crossref_primary_10_1111_liv_13397 crossref_primary_10_1097_MD_0000000000015940 crossref_primary_10_3389_fnut_2023_1239996 crossref_primary_10_1183_13993003_01923_2016 crossref_primary_10_3390_ijms21113863 crossref_primary_10_1007_s12325_017_0556_1 crossref_primary_10_1155_cjgh_5871321 crossref_primary_10_1186_s12944_019_0984_9 crossref_primary_10_1186_s12944_021_01617_3 crossref_primary_10_1007_s11901_019_00500_1 crossref_primary_10_3748_wjg_v22_i44_9674 crossref_primary_10_1111_liv_13329 crossref_primary_10_1038_s41598_022_25931_7 crossref_primary_10_1186_s12916_024_03315_0 crossref_primary_10_3390_jcm11051445 crossref_primary_10_1136_bmjopen_2023_081293 crossref_primary_10_1136_bmjopen_2018_025524 crossref_primary_10_1016_j_dld_2016_10_004 crossref_primary_10_3233_CBM_170157 crossref_primary_10_1016_j_ebiom_2016_05_021 crossref_primary_10_1002_hep4_2109 crossref_primary_10_3390_nu14245344 crossref_primary_10_1002_edm2_112 crossref_primary_10_3390_cells10112978 crossref_primary_10_3390_jcm7110458 crossref_primary_10_1007_s11695_021_05470_2 crossref_primary_10_3390_nu10080977 crossref_primary_10_1007_s12325_018_0670_8 crossref_primary_10_1007_s12079_023_00775_6 crossref_primary_10_1371_journal_pone_0174291 crossref_primary_10_1016_j_dld_2019_02_019 crossref_primary_10_3390_diagnostics11010098 crossref_primary_10_1183_13993003_00546_2017 crossref_primary_10_1002_ctd2_9 crossref_primary_10_1089_bari_2022_0043 crossref_primary_10_1186_s12876_019_0972_6 crossref_primary_10_3748_wjg_v23_i36_6571 crossref_primary_10_3748_wjg_v29_i4_597 crossref_primary_10_3389_fendo_2021_657856 crossref_primary_10_1007_s13300_020_00794_1 crossref_primary_10_3390_metabo14010040 crossref_primary_10_3389_fcimb_2024_1371543 crossref_primary_10_1002_ijc_30784 crossref_primary_10_1097_MEG_0000000000000865 crossref_primary_10_1080_17474124_2022_2016391 crossref_primary_10_3390_biomedicines9101491 crossref_primary_10_1155_2019_5939372 crossref_primary_10_1097_MEG_0000000000002807 crossref_primary_10_1016_j_imu_2024_101513 crossref_primary_10_4155_fmc_2019_0003 crossref_primary_10_1111_jgh_14813 crossref_primary_10_1002_med_21515 crossref_primary_10_1080_17474124_2018_1415756 crossref_primary_10_1080_17474124_2024_2435504 crossref_primary_10_1016_j_cld_2017_08_003 crossref_primary_10_3390_ijerph17082620 crossref_primary_10_1016_j_jhep_2016_08_019 crossref_primary_10_3390_medicina58020297 crossref_primary_10_1002_osp4_608 crossref_primary_10_1007_s10620_024_08808_9 crossref_primary_10_1016_j_phanu_2025_100429 crossref_primary_10_1002_jgm_3160 crossref_primary_10_1080_17425255_2017_1246534 crossref_primary_10_1371_journal_pone_0283743 crossref_primary_10_1111_apt_13782 crossref_primary_10_37349_emed_2020_00005 crossref_primary_10_1007_s40610_023_00156_3 crossref_primary_10_1371_journal_pone_0207043 crossref_primary_10_37349_emed_2020_00007 crossref_primary_10_3389_fmicb_2023_1131092 crossref_primary_10_1007_s12020_024_03888_z crossref_primary_10_1111_jgh_15850 crossref_primary_10_3390_ijms242417609 crossref_primary_10_1007_s00535_017_1364_8 crossref_primary_10_1136_bmjopen_2016_013543 crossref_primary_10_3390_ijms18091955 crossref_primary_10_1097_MEG_0000000000001658 crossref_primary_10_3390_diseases9030061 crossref_primary_10_1111_apt_17615 crossref_primary_10_1186_s12967_023_04047_0 crossref_primary_10_3390_ijms21186535 crossref_primary_10_1111_liv_13363 crossref_primary_10_1186_s12944_022_01712_z crossref_primary_10_1073_pnas_2018069118 crossref_primary_10_1038_nrgastro_2017_109 crossref_primary_10_1016_j_aohep_2020_03_001 crossref_primary_10_1016_j_cgh_2017_08_014 crossref_primary_10_3390_microorganisms9050957 crossref_primary_10_3390_nu9070774 |
Cites_doi | 10.1002/hep.24127 10.3748/wjg.v20.i11.3002 10.1002/hep.22724 10.1016/j.plipres.2012.11.002 10.1016/j.jhep.2012.11.021 10.1016/j.jhep.2008.11.021 10.1053/jhep.2003.50161 10.1007/s11739-011-0609-4 10.1016/j.dld.2015.08.004 10.1002/hep.24322 10.1002/hep.27173 10.1016/S1590-8658(02)80194-3 10.7326/0003-4819-145-4-200608150-00004 10.1111/apt.12255 10.3748/wjg.v20.i7.1724 10.1002/hep.26604 10.1053/jhep.2002.34443 10.1016/j.metabol.2012.08.013 10.1016/j.atherosclerosis.2013.10.030 10.1002/hep.27662 10.1194/jlr.M034876 10.1111/j.1572-0241.1999.01377.x 10.1586/17474124.2014.903798 10.1016/j.cgh.2009.06.007 10.1053/j.gastro.2007.10.024 10.1002/hep.26937 10.1002/hep.24706 10.1111/j.1365-2036.2011.04788.x 10.1016/j.jhep.2013.05.044 10.1093/eurheartj/eht151 10.2174/1381612811319290003 10.1016/j.jhep.2014.11.034 10.1002/hep.25762 10.1016/j.jhep.2013.02.024 10.3109/07853890.2010.518623 10.1016/j.dld.2010.01.021 10.1016/S2213-8587(14)70032-4 10.1016/j.amjcard.2012.08.012 10.1007/BF00280883 10.1002/hep.23094 10.7150/ijms.8951 10.1053/jhep.2002.32527 10.1053/j.gastro.2015.04.043 10.1053/j.gastro.2011.06.040 10.1111/liv.12842 10.1161/CIRCULATIONAHA.109.192644 10.1002/hep.23784 10.1136/jcp.2010.079145 10.1016/j.clinbiochem.2014.01.029 10.1002/hep.24268 10.1016/j.dld.2014.09.020 10.1016/j.cld.2012.05.009 10.1016/S0168-8278(14)60993-4 10.1586/egh.11.19 10.1002/hep.20701 10.2337/dc14-1239 |
ContentType | Journal Article |
Copyright | 2016 The Japan Society of Hepatology. |
Copyright_xml | – notice: 2016 The Japan Society of Hepatology. |
DBID | AAYXX CITATION NPM 7X8 |
DOI | 10.1111/hepr.12656 |
DatabaseName | CrossRef PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1872-034X |
EndPage | 1087 |
ExternalDocumentID | 26785389 10_1111_hepr_12656 |
Genre | Journal Article |
GroupedDBID | --- --K .3N .GA .Y3 05W 0R~ 10A 1B1 1OC 1~5 29I 31~ 33P 3SF 4.4 4G. 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AAHQN AAIPD AALRI AAMNL AANHP AANLZ AAONW AAQFI AAQXK AASGY AAXRX AAXUO AAYCA AAYXX AAZKR ABCQN ABCUV ABDBF ABEML ABIJN ABJNI ABPVW ABQWH ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACIUM ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACVFH ACXBN ACXQS ACYXJ ADBBV ADBTR ADCNI ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUPX AEUYR AEYWJ AFBPY AFFPM AFGKR AFPUW AFWVQ AFZJQ AGHNM AGQPQ AGYGG AHBTC AIACR AIAGR AIGII AITUG AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG CITATION COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD ESX EX3 F00 F01 F04 F5P FDB FEDTE FGOYB FUBAC G-Q G-S G.N GODZA H.X HF~ HGLYW HVGLF HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NQ- O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K R2- RIG ROL RPZ RX1 SEW SSZ SUPJJ TEORI TUS UB1 UHS V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR XG1 ZZTAW ~IA ~WT NPM 7X8 AAMMB AEFGJ AGXDD AIDQK AIDYY |
ID | FETCH-LOGICAL-c357t-966c4c385175ba96aeeeadbfc117aa133831d28d87cf2f3b3efdbd2b3e66736b3 |
ISSN | 1386-6346 |
IngestDate | Thu Jul 10 21:58:20 EDT 2025 Thu Apr 03 07:09:33 EDT 2025 Thu Apr 24 23:05:41 EDT 2025 Tue Jul 01 01:58:16 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | inflammatory grading HOMA-IR iron NAFLD fibrosis steatosis |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2016 The Japan Society of Hepatology. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c357t-966c4c385175ba96aeeeadbfc117aa133831d28d87cf2f3b3efdbd2b3e66736b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 26785389 |
PQID | 1826648581 |
PQPubID | 23479 |
PageCount | 14 |
ParticipantIDs | proquest_miscellaneous_1826648581 pubmed_primary_26785389 crossref_primary_10_1111_hepr_12656 crossref_citationtrail_10_1111_hepr_12656 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-10-00 2016-Oct 20161001 |
PublicationDateYYYYMMDD | 2016-10-01 |
PublicationDate_xml | – month: 10 year: 2016 text: 2016-10-00 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Hepatology research |
PublicationTitleAlternate | Hepatol Res |
PublicationYear | 2016 |
References | e_1_2_6_51_1 e_1_2_6_53_1 e_1_2_6_32_1 e_1_2_6_30_1 e_1_2_6_19_1 e_1_2_6_13_1 e_1_2_6_36_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_17_1 e_1_2_6_55_1 e_1_2_6_15_1 e_1_2_6_38_1 e_1_2_6_57_1 e_1_2_6_43_1 e_1_2_6_20_1 e_1_2_6_41_1 e_1_2_6_9_1 e_1_2_6_5_1 e_1_2_6_7_1 e_1_2_6_24_1 e_1_2_6_49_1 e_1_2_6_3_1 e_1_2_6_22_1 e_1_2_6_28_1 e_1_2_6_45_1 e_1_2_6_26_1 e_1_2_6_47_1 e_1_2_6_52_1 e_1_2_6_54_1 e_1_2_6_10_1 e_1_2_6_31_1 e_1_2_6_50_1 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_12_1 e_1_2_6_33_1 e_1_2_6_18_1 e_1_2_6_39_1 e_1_2_6_56_1 e_1_2_6_16_1 e_1_2_6_37_1 e_1_2_6_58_1 e_1_2_6_42_1 e_1_2_6_21_1 e_1_2_6_40_1 e_1_2_6_8_1 e_1_2_6_4_1 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (e_1_2_6_29_1) 2002; 25 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_48_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_44_1 e_1_2_6_27_1 e_1_2_6_46_1 |
References_xml | – ident: e_1_2_6_14_1 doi: 10.1002/hep.24127 – ident: e_1_2_6_56_1 doi: 10.3748/wjg.v20.i11.3002 – ident: e_1_2_6_17_1 doi: 10.1002/hep.22724 – ident: e_1_2_6_46_1 doi: 10.1016/j.plipres.2012.11.002 – ident: e_1_2_6_11_1 doi: 10.1016/j.jhep.2012.11.021 – ident: e_1_2_6_37_1 doi: 10.1016/j.jhep.2008.11.021 – ident: e_1_2_6_42_1 doi: 10.1053/jhep.2003.50161 – ident: e_1_2_6_44_1 doi: 10.1007/s11739-011-0609-4 – ident: e_1_2_6_3_1 doi: 10.1016/j.dld.2015.08.004 – ident: e_1_2_6_16_1 doi: 10.1002/hep.24322 – ident: e_1_2_6_32_1 doi: 10.1002/hep.27173 – ident: e_1_2_6_36_1 doi: 10.1016/S1590-8658(02)80194-3 – ident: e_1_2_6_27_1 doi: 10.7326/0003-4819-145-4-200608150-00004 – ident: e_1_2_6_55_1 doi: 10.1111/apt.12255 – ident: e_1_2_6_7_1 doi: 10.3748/wjg.v20.i7.1724 – ident: e_1_2_6_48_1 doi: 10.1002/hep.26604 – ident: e_1_2_6_50_1 doi: 10.1053/jhep.2002.34443 – ident: e_1_2_6_39_1 doi: 10.1016/j.metabol.2012.08.013 – ident: e_1_2_6_52_1 doi: 10.1016/j.atherosclerosis.2013.10.030 – ident: e_1_2_6_57_1 doi: 10.1002/hep.27662 – ident: e_1_2_6_47_1 doi: 10.1194/jlr.M034876 – ident: e_1_2_6_8_1 doi: 10.1111/j.1572-0241.1999.01377.x – ident: e_1_2_6_22_1 doi: 10.1586/17474124.2014.903798 – ident: e_1_2_6_41_1 doi: 10.1016/j.cgh.2009.06.007 – ident: e_1_2_6_4_1 doi: 10.1053/j.gastro.2007.10.024 – ident: e_1_2_6_19_1 doi: 10.1002/hep.26937 – ident: e_1_2_6_20_1 doi: 10.1002/hep.24706 – ident: e_1_2_6_25_1 doi: 10.1111/j.1365-2036.2011.04788.x – ident: e_1_2_6_2_1 doi: 10.1016/j.jhep.2013.05.044 – ident: e_1_2_6_30_1 doi: 10.1093/eurheartj/eht151 – ident: e_1_2_6_6_1 doi: 10.2174/1381612811319290003 – ident: e_1_2_6_35_1 doi: 10.1016/j.jhep.2014.11.034 – ident: e_1_2_6_9_1 doi: 10.1002/hep.25762 – ident: e_1_2_6_53_1 doi: 10.1016/j.jhep.2013.02.024 – ident: e_1_2_6_5_1 doi: 10.3109/07853890.2010.518623 – ident: e_1_2_6_12_1 doi: 10.1016/j.dld.2010.01.021 – ident: e_1_2_6_21_1 doi: 10.1016/S2213-8587(14)70032-4 – ident: e_1_2_6_38_1 doi: 10.1016/j.amjcard.2012.08.012 – ident: e_1_2_6_28_1 doi: 10.1007/BF00280883 – ident: e_1_2_6_51_1 doi: 10.1002/hep.23094 – volume: 25 start-page: S1 year: 2002 ident: e_1_2_6_29_1 article-title: American Diabetes Association: Clinical practice recommendations publication-title: Diabetes Care – ident: e_1_2_6_43_1 doi: 10.7150/ijms.8951 – ident: e_1_2_6_49_1 doi: 10.1053/jhep.2002.32527 – ident: e_1_2_6_10_1 doi: 10.1053/j.gastro.2015.04.043 – ident: e_1_2_6_45_1 doi: 10.1053/j.gastro.2011.06.040 – ident: e_1_2_6_40_1 doi: 10.1111/liv.12842 – ident: e_1_2_6_31_1 doi: 10.1161/CIRCULATIONAHA.109.192644 – ident: e_1_2_6_24_1 doi: 10.1002/hep.23784 – ident: e_1_2_6_18_1 doi: 10.1136/jcp.2010.079145 – ident: e_1_2_6_26_1 doi: 10.1016/j.clinbiochem.2014.01.029 – ident: e_1_2_6_15_1 doi: 10.1002/hep.24268 – ident: e_1_2_6_23_1 doi: 10.1016/j.dld.2014.09.020 – ident: e_1_2_6_33_1 doi: 10.1016/j.cld.2012.05.009 – ident: e_1_2_6_58_1 doi: 10.1016/S0168-8278(14)60993-4 – ident: e_1_2_6_34_1 doi: 10.1586/egh.11.19 – ident: e_1_2_6_13_1 doi: 10.1002/hep.20701 – ident: e_1_2_6_54_1 doi: 10.2337/dc14-1239 |
SSID | ssj0017024 |
Score | 2.5047176 |
Snippet | The diagnosis of non-alcoholic steatohepatitis (NASH) is based on the individual histological features: steatosis, lobular inflammation and ballooning.... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 1074 |
Subtitle | Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment |
Title | The independent predictors of non‐alcoholic steatohepatitis and its individual histological features |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26785389 https://www.proquest.com/docview/1826648581 |
Volume | 46 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Lb9MwGLfKJiEuiDflJSO4oClTHTtOclyBqkKMA9qk3SI_RaStQW164cSfwJV_j7-Ez7HjhNFJg0taObHT-vvpe_l7IPSaghJsrGVJKVKeMJaZpLBaJRJulCw3OdXOoX_8iS9P2Yez7Gwy-TmKWtq28lB925lX8j9UhTGgq8uS_QfKxkVhAL4DfeEKFIbrtWlcxz62rUv417Xvn-PiM0Cr60MZhO-EW6sDR9W2-WJcJHVbb-LhQT1kZnU1iHueaE1X-nMz1mKXbrYv3hSKBUWn8tz1ZnG9QEIImRWrJjqcBcjbC2m6LlIHCyHreOtzc-FC_s77tPc24u0jmApr7ZNxQHKbZuynIDxGvPWslRY84TQ4HI0fK_I0mVEfo9nz4_BEwB0ZcVcXPDqS1GTmZfUVUgB2cn1IUp7tKLV9SQTGwMTeJHJzq27uDbSfggUCLHT_aP5uvohHVPksdEwOfyvUvnVhYsOb_9R2rjBhOlXm5A66HWwQfOQBdRdNzOoeunkcoizuIwu4wiNc4QFXuLEYcPXr-4-IKHwJURgQhQFReEAUHiMK94h6gE4X70_eLpPQjyNRNMtbV8hVMUVBR88zKUoujAE-JK0iJBeic3YQnRa6yJVNLZXUWC11Cp-utyyX9CHag59oHiPMNKxYOolALYPJhZSKG65zYpnJuJ6iN_2-VSoUq3c9U86rvyk0Ra_is199iZadT73st78CDuqOxcTKNNtN5SxszoqsIFP0yNMlrpOCLgcqQfnkWu94im4NyH-G9tr11jwHnbWVLwJ6fgOkvp9j |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+independent+predictors+of+non%E2%80%90alcoholic+steatohepatitis+and+its+individual+histological+features&rft.jtitle=Hepatology+research&rft.au=Ballestri%2C+Stefano&rft.au=Nascimbeni%2C+Fabio&rft.au=Romagnoli%2C+Dante&rft.au=Lonardo%2C+Amedeo&rft.date=2016-10-01&rft.issn=1386-6346&rft.eissn=1872-034X&rft.volume=46&rft.issue=11&rft.spage=1074&rft.epage=1087&rft_id=info:doi/10.1111%2Fhepr.12656&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_hepr_12656 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1386-6346&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1386-6346&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1386-6346&client=summon |